NCT03515382 is a Phase 1 clinical trial of GLPG1690 in Healthy, sponsored by Galapagos NV.

Who is sponsoring NCT03515382?

NCT03515382 is sponsored by Galapagos NV.

What drugs are being tested in NCT03515382?

Interventions in NCT03515382: GLPG1690, Itraconazole, Voriconazole.

Is NCT03515382 still recruiting?

NCT03515382 is currently completed. Last updated 11 June 2018.

Last reviewed 2018-06-11 · How we verify

NCT03515382

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

Completed Phase 1 Last updated 11 June 2018

What this trial tests

Phase 1 trial testing GLPG1690 in Healthy in 18 participants. Completed in 1 June 2018.

Timeline

16 March 2018

Primary endpoint
1 June 2018

1 June 2018

Quick facts

Lead sponsor	Galapagos NV
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	18
Start date	16 March 2018
Primary completion	1 June 2018
Estimated completion	1 June 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

GLPG1690 — full drug profile →
Itraconazole — full drug profile →
Voriconazole — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Galapagos NV — full company profile →

Who can join

Adults 18 to 55, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The sponsor wants to investigate how well the test medicine is taken up by the body when given alongside two other already approved medicines. This kind of study is known as a drug-drug interaction study. In this case the other medicines are itraconazole and voriconazole. The sponsor will also look at the safety and tolerability of the test medicine when taken alone, and when taken with the approved medicines.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacophoric Site Identification and Inhibitor Design for Autotaxin.
Lee MH, Lee DY, Balupuri A, Jeong JW, et al · · 2019 · cited 6× · PMID 31374894 · DOI 10.3390/molecules24152808

Verify or expand the search:

Other trials of GLPG1690

Trials testing the same drug.

NCT03976648 — A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis · Phase 2 · terminated
NCT03798366 — A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis · Phase 2 · completed
NCT03711162 — A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When U · Phase 3 · terminated
NCT03733444 — A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) Wh · Phase 3 · terminated
NCT03143712 — Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet · Phase 1 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Galapagos NV trials

Trials by the same sponsor.

NCT06043739 — Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects · Phase 1 · completed
NCT05856448 — A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lup · Phase 2 · completed
NCT05479058 — A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission · Phase 3 · terminated
NCT05335447 — Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667 · Phase 1 · completed
NCT06561425 — A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03515382 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Galapagos NV
Last refreshed: 11 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03515382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing